Evidence map›Paper›PMID 40790072›Full record

ArticleScientific reports2025

Discovery of potent endolysins against Pseudomonas aeruginosa and other gram-negative ESKAPE pathogens by an agar-based screening method.

Vera Oberbauer, Michele Mutti, Timo Schwebs, Svetlana Durica-Mitic, Zehra Visram, Donaat Kestemont, Adriana Badarau, Lorenzo Corsini

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vera OberbauerBioNTech R&D (Austria) GmbH, Vienna, Austria.
Michele MuttiBioNTech R&D (Austria) GmbH, Vienna, Austria.
Timo SchwebsBioNTech R&D (Austria) GmbH, Vienna, Austria.
Svetlana Durica-MiticBioNTech R&D (Austria) GmbH, Vienna, Austria.
Zehra VisramBioNTech R&D (Austria) GmbH, Vienna, Austria.
Donaat KestemontBioNTech R&D (Austria) GmbH, Vienna, Austria.
Adriana BadarauBioNTech R&D (Austria) GmbH, Vienna, Austria.
Lorenzo CorsiniBioNTech R&D (Austria) GmbH, Vienna, Austria. lorenzo.corsini@biontech.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotic resistance is a growing concern, and there is an urgent need for alternative treatments. A proposed solution includes endolysins. Naturally occurring endolysins have limited activity against Gram-negative bacteria due to the presence of an outer membrane. Previous agar-based screening methods did not consider this and screened for activity on autoclaved cell debris. In this study, we used a soft-agar-based screening method to identify endolysins targeting Pseudomonas aeruginosa. This method enabled us to screen for activity of endolysins on live Pseudomonas aeruginosa, taking the outer membrane into account. The application of this randomized forward screening method led to the discovery of three highly bactericidal endolysins, L0779, L0782, and L0799. These endolysins displayed a broad spectrum of activity against other Gram-negative bacterial species. We report minimal inhibitory concentrations (MICs) for endolysins acting on multiple Gram-negative ESKAPE species, with MICs for L0782 on Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii ranging from 4 to 16 µg/mL. In summary, our screening method enables rapid identification of endolysins with broad-spectrum activity against Gram-negative bacteria. These show potential for further development as alternative treatments for antibiotic-resistant infections.

Indexed as

Anti-Bacterial AgentsEndopeptidasesGram-Negative BacteriaPseudomonas aeruginosaAgarMicrobial Sensitivity TestsAgarAnti-Bacterial AgentsendolysinEndopeptidases

Identifiers

PMID40790072
PMCPMC12339961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.